120 related articles for article (PubMed ID: 26158298)
1. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
[TBL] [Abstract][Full Text] [Related]
2. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.
Eguchi T; Kadota K; Chaft J; Evans B; Kidd J; Tan KS; Dycoco J; Kolquist K; Davis T; Hamilton SA; Yager K; Jones JT; Travis WD; Jones DR; Hartman AR; Adusumilli PS
Oncotarget; 2016 Jun; 7(23):35241-56. PubMed ID: 27153551
[TBL] [Abstract][Full Text] [Related]
4. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators.
Rakha E; Pajares MJ; Ilie M; Pio R; Echeveste J; Hughes E; Soomro I; Long E; Idoate MA; Wagner S; Lanchbury JS; Baldwin DR; Hofman P; Montuenga LM
Eur J Cancer; 2015 Sep; 51(14):1897-903. PubMed ID: 26235745
[TBL] [Abstract][Full Text] [Related]
5. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
6. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
7. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
Lu Y; Wang L; Liu P; Yang P; You M
PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
[TBL] [Abstract][Full Text] [Related]
8. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
[TBL] [Abstract][Full Text] [Related]
9. Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes.
Dancik GM; Theodorescu D
PLoS One; 2014; 9(1):e85249. PubMed ID: 24465512
[TBL] [Abstract][Full Text] [Related]
10. A novel seven-long non-coding RNA signature predicts survival in early stage lung adenocarcinoma.
Chen M; Liu B; Xiao J; Yang Y; Zhang Y
Oncotarget; 2017 Feb; 8(9):14876-14886. PubMed ID: 28122330
[TBL] [Abstract][Full Text] [Related]
11. Increased S100A15 expression and decreased DNA methylation of its gene promoter are involved in high metastasis potential and poor outcome of lung adenocarcinoma.
Chen YC; Lin MC; Hsiao CC; Zheng YX; Chen KD; Sung MT; Chen CJ; Wang TY; Lin YY; Chang HC; Chen YM; Chang JC
Oncotarget; 2017 Jul; 8(28):45710-45724. PubMed ID: 28498804
[TBL] [Abstract][Full Text] [Related]
12. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
13. Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction.
Wan YW; Sabbagh E; Raese R; Qian Y; Luo D; Denvir J; Vallyathan V; Castranova V; Guo NL
PLoS One; 2010 Aug; 5(8):e12222. PubMed ID: 20808922
[TBL] [Abstract][Full Text] [Related]
14. Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients.
Ly D; Zhu CQ; Cabanero M; Tsao MS; Zhang L
Cancer Immunol Res; 2017 Sep; 5(9):821-829. PubMed ID: 28775209
[TBL] [Abstract][Full Text] [Related]
15. A simple two-gene prognostic model for adenocarcinoma of the lung.
Reed CE; Graham A; Hoda RS; Khoor A; Garrett-Mayer E; Wallace MB; Mitas M
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):627-34. PubMed ID: 18329483
[TBL] [Abstract][Full Text] [Related]
16. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.
Kadara H; Behrens C; Yuan P; Solis L; Liu D; Gu X; Minna JD; Lee JJ; Kim E; Hong WK; Wistuba II; Lotan R
Clin Cancer Res; 2011 Mar; 17(6):1490-501. PubMed ID: 21163870
[TBL] [Abstract][Full Text] [Related]
17. Small RNA sequencing reveals metastasis-related microRNAs in lung adenocarcinoma.
Daugaard I; Venø MT; Yan Y; Kjeldsen TE; Lamy P; Hager H; Kjems J; Hansen LL
Oncotarget; 2017 Apr; 8(16):27047-27061. PubMed ID: 28460486
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA CASC9.5 promotes the proliferation and metastasis of lung adenocarcinoma.
Zhou J; Xiao H; Yang X; Tian H; Xu Z; Zhong Y; Ma L; Zhang W; Qiao G; Liang J
Sci Rep; 2018 Jan; 8(1):37. PubMed ID: 29311567
[TBL] [Abstract][Full Text] [Related]
19. Genome-scale meta-analysis of DNA methylation during progression of lung adenocarcinoma.
Zhang QH; Dai XH; Dai ZM; Cai YN
Genet Mol Res; 2015 Aug; 14(3):9200-14. PubMed ID: 26345853
[TBL] [Abstract][Full Text] [Related]
20. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes.
Bianchi F; Nuciforo P; Vecchi M; Bernard L; Tizzoni L; Marchetti A; Buttitta F; Felicioni L; Nicassio F; Di Fiore PP
J Clin Invest; 2007 Nov; 117(11):3436-44. PubMed ID: 17948124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
